MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Organon & Co. Common Stock (NY:OGN)

7.375 +0.315 (+4.46%)
Streaming Delayed Price Updated: 3:19 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,480,748
Open 7.020
Bid (Size) 7.370 (2,000)
Ask (Size) 7.380 (800)
Prev. Close 7.060
Today's Range 6.973 - 7.580
52wk Range 6.180 - 17.23
Shares Outstanding 259,965,579
Dividend Yield 1.08%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
OGN Q4 Deep Dive: Margin Compression and U.S. Headwinds Shape 2026 Outlook
Pharmaceutical company Organon (NYSE:OGN) met Wall Street’s revenue expectations in Q4 CY2025, but sales fell by 5.3% year on year to $1.51 billion. The company’s full-year revenue guidance of $6.2... 
Via StockStory
News headline image
Organon (OGN) Q4 2025 Earnings Call Transcript ↗
Organon (OGN) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings

Performance

YTD
+1.9%
+1.9%
1 Month
-12.5%
-12.5%
3 Month
-3.2%
-3.2%
6 Month
-21.5%
-21.5%
1 Year
-49.8%
-49.8%

More News

Read More
Organon & Co (NYSE:OGN) Shares Drop on Q4 Earnings Miss and Flat 2026 Outlook ↗
Via Chartmill
Topics Earnings
News headline image
Organon (NYSE:OGN) Reports Q4 CY2025 In Line With Expectations
Via StockStory
News headline image
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025
From Organon & Co.
Via Business Wire
News headline image
Organon Earnings: What To Look For From OGN
Via StockStory
Topics Artificial Intelligence World Trade
News headline image
2 Healthcare Stocks with Promising Prospects and 1 We Brush Off
Via StockStory
Topics Stocks
News headline image
Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026
From Organon & Co.
Via Business Wire
News headline image
Organon Completes Divestiture of JADA® System to Laborie
From Organon & Co.
Via Business Wire
News headline image
The Post-Keytruda Pivot: Inside Merck’s Strategic Evolution and the RVMD Landscape
Via Finterra
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Stability Meets Scale: Why Johnson & Johnson is Poised for a Breakout 2026
Via MarketMinute
Topics Artificial Intelligence Bankruptcy Economy
News headline image
Nasdaq, S&P 500 Futures Rise As Trump Diffuses Tariff Risk: Why INTC, MSFT, NFLX, RKLB, OGN Are On Traders' Radar Today ↗
Via Stocktwits
Topics ETFs Earnings Economy
News headline image
Why Are Organon (OGN) Shares Soaring Today
Via StockStory
Topics Artificial Intelligence Initial Public Offering Supply Chain
News headline image
Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque
From Organon & Co.
Via Business Wire
News headline image
3 Small-Cap Stocks We Approach with Caution
Via StockStory
News headline image
3 Healthcare Stocks with Questionable Fundamentals
Via StockStory
Topics Stocks
News headline image
Why Organon (OGN) Shares Are Trading Lower Today
Via StockStory
Topics Initial Public Offering
News headline image
3 Stocks Under $10 We Steer Clear Of
Via StockStory
News headline image
3 Value Stocks with Questionable Fundamentals
Via StockStory
News headline image
3 Cash-Producing Stocks We Find Risky
Via StockStory
News headline image
Organon (OGN): Buy, Sell, or Hold Post Q3 Earnings?
Via StockStory
Topics Stocks
News headline image
Q3 Rundown: Organon (NYSE:OGN) Vs Other Branded Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Organon To Present at the Piper Sandler 37th Annual Healthcare Conference
From Organon & Co.
Via Business Wire
News headline image
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US
From Organon & Co.
Via Business Wire
News headline image
The 5 Most Interesting Analyst Questions From Organon’s Q3 Earnings Call
Via StockStory
Topics Earnings

Frequently Asked Questions

Is Organon & Co. Common Stock publicly traded?
Yes, Organon & Co. Common Stock is publicly traded.
What exchange does Organon & Co. Common Stock trade on?
Organon & Co. Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Organon & Co. Common Stock?
The ticker symbol for Organon & Co. Common Stock is OGN on the New York Stock Exchange
What is the current price of Organon & Co. Common Stock?
The current price of Organon & Co. Common Stock is 7.375
When was Organon & Co. Common Stock last traded?
The last trade of Organon & Co. Common Stock was at 02/13/26 03:19 PM ET
What is the market capitalization of Organon & Co. Common Stock?
The market capitalization of Organon & Co. Common Stock is 1.92B
How many shares of Organon & Co. Common Stock are outstanding?
Organon & Co. Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story